Zhengzhou Handu Pharmaceutical Co. Ltd.

The primary objective was to investigate the pharmacokinetic characteristics of the test formulation, arginine ibuprofen granules (strength: 0.4 g (ibuprofen); manufacturer: Zhengzhou Handu Pharmaceutical Group Co., Ltd.) and the reference formulation, arginine ibuprofen granules (trade name: SPECTREX®; strength: 0.4 g (ibuprofen); manufacturer and licensee: Hainan Zanbang Pharmaceutical Co., Ltd.), in healthy Chinese volunteers under fasting and fed conditions, and to evaluate the bioequivalence of the two formulations in healthy subjects under fasting and fed conditions. The secondary objective was to investigate the safety of the test formulation, arginine ibuprofen granules, and the reference formulation, arginine ibuprofen granules (SPECTREX®), in healthy Chinese volunteers.

The main purpose of the study is to investigate the pharmacokinetic characteristics of a single oral dose (fasting/postprandial) of 80 mg of the test preparation, mersartan potassium tablets, and the reference preparation, mersartan potassium tablets, in healthy adult Chinese participants, and to evaluate the bioequivalence of the two preparations when taken orally under fasting and postprandial conditions. The secondary purpose of the study is to evaluate the safety of a single oral dose of 80 mg (fasting/postprandial) of the test preparation and the reference preparation in healthy adult Chinese participants.

Main purpose: This study used Olopatadine Hydrochloride Tablets certified by Zhengzhou Handu Pharmaceutical Group Co., Ltd. as the test preparation and Olopatadine Hydrochloride Tablets (trade name: Allelock) certified by Kyowa Kirin Co., Ltd. as the reference preparation to conduct a human bioequivalence test under fasting/fed conditions. Secondary purpose: To evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects.